Tag: R-Pharm

R-Pharm is a Russian private hi-tech pharmaceutical company founded in 2001, employs over 3500 highly qualified specialists, has over 60 branches. Turnover reached over $ 1,5 billion in 2013. R-Pharm operates in Russia and CIS, USA, Germany, Japan and India. The company is involved in R&D, manufacturing, marketing, sales and distribution of innovative pharmaceutical products from a broad number of therapeutic areas in specialty/hospital care. The company has operational GMP compliant manufacturing sites at Yaroslavl, Kostroma region and Germany and Novosibirsk/ R-Pharm is building a modern facility for the synthesis of active pharmaceutical ingredients in Rostov – Pharmoslavl. It is expected that the first phase of Pharmoslavl site will be put into operation in the end of 2016. The new facility will comply with the highest requirements of environmental and occupational safety and health standards for the workplace.

Over the time of operation of its manufacturing facilities the company has successfully passed audits and evaluation visits from the largest Global Pharma companies, such as Abbvie, Amgen, Astellas, AstraZeneca, BMS, Boryung, Dr.Reddy’s, Eli Lilly, Ferring, Glaxo Smith Kline, Johnson& Johnson, Mallinckrodt, MSD, Pfizer, Roche, and Sanofi. The R-Pharm’s facilities in the Yaroslavl and Kostroma regions implement dozens of complex advanced production technologies, which haven’t been used previously in the Russian Federation.

R-Pharm has invested in the establishment of biopharmaceutical products manufacturing facility based on FlexFactory processing line from the U.S. company Xcellerex. This facility is the first step towards the mass production of biologic drugs including innovative products and biosimilars. The plant will simultaneously be certified in the USA to meet the FDA and GMP requirements and will be the first of its kind production in Russia. Through this project the company will be able to deliver innovative medicines for the treatment of many socially significant diseases. As part of the investment agreement, Xcellerex will provide training to R-Pharm specialists in order to ensure the most rapid and effective transfer of technology and knowledge in accordance with GMP production standards and the requirements of international regulatory bodies.

R-Pharm specializes in the supply of high-tech medicinal products and laboratory equipment for the leading federal medical research centers, hospitals and clinical hospitals, as well as the largest regional curative and preventive care institutions of the Russian Federation.

The company’s portfolio includes medicinal products of various pharmaceutical groups, including oncology, hematology, cardiology, immunology, antibacterial, anti-viral, including the treatment of HIV-infection, medicinal products used in organ transplantation, treatment of disseminated sclerosis, hemophilia and diabetes, as well as neuromuscular relaxants, radiopaque contrast agents and drugs for anesthesia.

The company’s core businesses are manufacturing of finished dosage forms, active pharmaceutical ingredients of chemical nature and biotech substances; research and development of innovative products and technologies; bringing the highly efficient pharmaceutical products to the Russian market; as well as implementation of education and training programs for pharmaceutical and healthcare industries.

R-Pharm Kazakhstan receives a GDP compliance certificate

In February 2018, the division of R-Pharm Group in Kazakhstan received a certificate of compliance with the Good Distribution Practice (GDP) from the Ministry of Health of the Republic of Kazakhstan. ...

R-Pharm and Human Longevity will establish genome analysis centers in Russia

R-Pharm, a Russian group of companies, and Human Longevity, Inc., an American corporation, have signed an agreement on collaboration in the area of human genome research and diagnostics

TaiGen and R-Pharm completed patient enrollment for clinical trials of Taigexyn

clinical trials
TaiGen Biotechnology Company, Ltd. and R-Pharm Group announced the completion of patient enrollment for phase III clinical trials of Taigexyn

R-Pharm localized full-cycle manufacturing of Glatirat

Yaroslavl Plant of Finished Dosage Forms and Biotechnological Substances completed the project to localize the full-cycle manufacturing of Glatirat

R-Pharm and PrimeBioMed will develop a quantitative immunohistochemical test

R-Pharm Group and PrimeBioMed LLC signed an agreement on joint development of a quantitative immunohistochemical test for the use of drugs blocking PD-1/PD-L1

R-Pharm completes the deal to sell a 10% stake to Mitsui

October 17 marked the closing of a deal on acquisition of a 10% stake in R-Pharm, a Russian pharmaceutical company, by Mitsui & Co., Ltd.

R-Pharm becomes the first Russian company to conduct clinical trials in South Korea

A meeting with the doctors and employees of 8 leading South Korean clinical and university centers was held in Seoul.

A fund established by RDIF and JBIC invests in R-Pharm

The first deal of the joint investment fund established by Japan Bank for International Cooperation and Russian Direct Investment Fund will be investment in R-Pharm

R-Pharm will help to introduce innovative diagnostic methods in Kazakhstan

On August 26, during the Eurasian Week held in Astana, ULNANOTECH, LLP R-Pharm Kazakhstan and LLC TestGen signed a cooperation agreement.

Phase III clinical study of Remimazolam starts in Russia

R-Pharm began the Phase III clinical study of the medicine used to induce and maintain the general anesthesia

Otsuka and R-Pharm sign a licensing agreement to market Deltyba

Otsuka Pharmaceutical Co. Ltd. and R-Pharm Group signed a licensing agreement to manufacture and market Deltyba

R-Pharm and Aspyrian Therapeutics signed an exclusive licensing agreement

R-Pharm Overseas, Inc., a division of R-Pharm Group, signed an exclusive licensing agreement with Aspyrian Therapeutics Inc.

MSD and R-Pharm invested 200 million rubles in the localization of Raltegravir

MSD, an international biopharmaceutical company, and R-Pharm, a leading Russian pharmaceutical company, have announced the successful completion of their joint project

R-Pharm plans to launch its products onto the Japanese market

In three years, the Russian pharmaceutical company R-Pharm intends to launch some of its medicines onto the Japanese market.

R-Pharm and Nacimbio established a joint venture

National Immunobiological Company, a part of Rostec Corporation, and R-Pharm, a Russian pharmaceutical company, signed an agreement to establish a joint venture.

New product of R-Pharm will reduce the cost of HCV treatment

On April 25, Vladimir Putin met the representatives of businesses in the Yaroslavl region. The event was attended by Vasily Ignatiev, the CEO of R-Pharm Group. The CEO of R-Pharm mentioned the suppor...